Stanley Laman Group Ltd. continued to hold its stake in shares of Merck & Company, Inc. (NYSE:MRK) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 9,707 shares of the company’s stock at the end of the second quarter. Stanley Laman Group Ltd.’s holdings in Merck & were worth $622,000 at the end of the most recent quarter.
A number of other hedge funds have also recently made changes to their positions in the stock. RB Capital Management LLC boosted its position in shares of Merck & by 0.5% in the 2nd quarter. RB Capital Management LLC now owns 4,587 shares of the company’s stock valued at $294,000 after purchasing an additional 23 shares during the period. Baystate Wealth Management LLC boosted its position in shares of Merck & by 0.4% in the 2nd quarter. Baystate Wealth Management LLC now owns 6,470 shares of the company’s stock valued at $405,000 after purchasing an additional 27 shares during the period. Bath Savings Trust Co boosted its position in shares of Merck & by 0.5% in the 2nd quarter. Bath Savings Trust Co now owns 5,427 shares of the company’s stock valued at $348,000 after purchasing an additional 28 shares during the period. Camelot Portfolios LLC boosted its position in shares of Merck & by 0.4% in the 1st quarter. Camelot Portfolios LLC now owns 7,771 shares of the company’s stock valued at $494,000 after purchasing an additional 33 shares during the period. Finally, Stillwater Investment Management LLC boosted its position in shares of Merck & by 0.8% in the 2nd quarter. Stillwater Investment Management LLC now owns 4,621 shares of the company’s stock valued at $296,000 after purchasing an additional 38 shares during the period. 73.15% of the stock is owned by institutional investors and hedge funds.
Merck & Company, Inc. (NYSE MRK) opened at $55.10 on Tuesday. The company has a quick ratio of 1.16, a current ratio of 1.43 and a debt-to-equity ratio of 0.57. Merck & Company, Inc. has a one year low of $54.41 and a one year high of $66.80. The firm has a market capitalization of $151,151.77, a P/E ratio of 14.26, a P/E/G ratio of 2.39 and a beta of 0.78.
Merck & (NYSE:MRK) last issued its quarterly earnings data on Friday, October 27th. The company reported $1.11 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.03 by $0.08. Merck & had a return on equity of 27.08% and a net margin of 11.60%. The business had revenue of $10.33 billion for the quarter, compared to the consensus estimate of $10.54 billion. During the same period last year, the business earned $1.07 EPS. The firm’s revenue was down 2.0% compared to the same quarter last year. research analysts predict that Merck & Company, Inc. will post 3.95 earnings per share for the current fiscal year.
In related news, Director Thomas H. Glocer sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 8th. The stock was sold at an average price of $56.20, for a total value of $281,000.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.25% of the stock is currently owned by company insiders.
A number of research firms recently weighed in on MRK. Zacks Investment Research lowered Merck & from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. BMO Capital Markets reiterated a “buy” rating and issued a $72.00 price target on shares of Merck & in a research report on Friday, September 8th. UBS AG increased their price target on Merck & from $70.00 to $72.00 and gave the company a “buy” rating in a research report on Monday, July 31st. Piper Jaffray Companies set a $70.00 price target on Merck & and gave the company a “buy” rating in a research report on Saturday, July 29th. Finally, BidaskClub upgraded Merck & from a “sell” rating to a “hold” rating in a research report on Tuesday, August 1st. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the company. Merck & currently has a consensus rating of “Hold” and a consensus price target of $67.07.
COPYRIGHT VIOLATION NOTICE: “Merck & Company, Inc. (MRK) Position Held by Stanley Laman Group Ltd.” was first published by Markets Daily and is owned by of Markets Daily. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.themarketsdaily.com/2017/11/14/merck-company-inc-mrk-position-held-by-stanley-laman-group-ltd.html.
Merck & Company Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.